MASHINIi

PLUS THERAPEUTICS, Inc..

PSTV.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

PLUS Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for patients with cancer. The company's lead drug candidate is Rhenium-186 Nanoliposome (186RNL), a novel, liposomal-encapsulated radiotherapeutic being evaluated in clinical trials for the ...Show More

Ethical Profile

Mixed.

PLUS THERAPEUTICS, Inc. (PSTV.US) is dedicated to advancing health, focusing on radiotherapeutic treatments like REYOBIQ for aggressive cancers such as glioblastoma and pediatric brain cancers, and the CNSide Test for early detection, addressing significant unmet medical needs. However, the company faced a Nasdaq delinquency notification in May 2025 for a delayed quarterly report, though compliance was reportedly regained. Employee sentiment, based on Glassdoor reviews, indicates a mixed experience with an overall 2.9 rating and 30% CEO approval, with some reports suggesting 'chaotic management' and employees feeling 'overworked,' despite positive mentions of remote work and healthcare benefits. Many other ethical areas lack sufficient public data for a comprehensive assessment.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect-20
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech-30
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess PLUS THERAPEUTICS, Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

PLUS Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing cancer therapies. The provided articles detail its financial performance, clinical trials, regulatory approvals for drug candidates, and corporate financing activities. There is no evidence that the company offers lending, insurance, or other financial services to consumers or businesses.

1
Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to this company's core business model.

Fair Pay & Worker Respect

-20

The company has an overall employee rating of 2.9 out of 5, which corresponds to 58% satisfaction.

1
The CEO approval rating stands at 30%.
2
Employee reviews highlight pros such as remote work, good healthcare, fair PTO, and meaningful cancer research.
3
However, cons include chaotic and illogical management, executives hired for appearances, and management not caring about employees.
4

Fair Trade & Ethical Sourcing

0

No data was found in the provided articles to assess PSTV.US's fair trade and ethical sourcing practices.

1
Both articles indicated 'Page Not Found' errors, resulting in no available information for any of the KPIs.
2

Honest & Fair Business

0

The company received a Nasdaq delinquency notification for a delayed filing.

1
However, these events do not provide specific monetary values for ethics-related regulatory fines, scores from recognized transparency benchmarks, or other quantifiable data points required by the rubric's KPIs. Therefore, no KPIs can be scored based on the provided evidence.

Kind to Animals

0

PLUS Therapeutics, Inc. is listed as a company that conducts animal testing.

1
No specific data is available regarding the company's animal testing policies, the volume of animals used, or any efforts to adopt alternative testing methods or humane certifications.
2

No War, No Weapons

0

PLUS Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for cancer.

1
The provided articles consistently state that the company's core business is in the pharmaceutical sector and is not involved in arms, defense, or conflict-related activities. While the company received a $3 million award recommendation from the US Department of Defense, this funding is specifically for pediatric brain cancer treatment research, not for arms or defense contracts, and is an expected future award, not current revenue.
2
There is no evidence of the company engaging in arms manufacturing, military contracts, dual-use technology with military applications, sales to embargoed regimes, or any other conflict-facilitating activities.

Planet-Friendly Business

0

No specific, concrete data points or information relevant to PSTV.US's environmental performance were found across the provided articles. The articles either explicitly stated they did not contain data for PSTV.US or indicated that content could not be retrieved.

Respect for Cultures & Communities

0

No evidence available to assess PLUS THERAPEUTICS, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

-30

The company's Terms of Use state that users can view, change, or withdraw consent for their data.

1
However, the document only mentions password-protected areas requiring registration and password changes, with no mention of multi-factor authentication (MFA) options, indicating a lack of advanced authentication security.
2

Zero Waste & Sustainable Products

0

No specific data or information related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was provided in the article.

1

Own PLUS THERAPEUTICS, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.